MapLight Therapeutics (MPLT) Return on Capital Employed (2025)

MapLight Therapeutics' (MPLT) quarterly Return on Capital Employed came in at 45.02% in Q4 2025.

MapLight Therapeutics (MPLT) Return on Capital Employed (2025) Analysis & Trends

MapLight Therapeutics has disclosed Return on Capital Employed across 1 years of filings, most recently posting 45.02% for Q4 2025.

Return on Capital Employed for Q4 2025 came in at 45.02%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was 45.02% (changed N/A YoY), and the FY2025 annual result was 57.91%, changed N/A from the prior year.
Return on Capital Employed came in at 45.02% for Q4 2025 at MapLight Therapeutics.
In the past five years, Return on Capital Employed ranged from a high of 45.02% in Q4 2025 to a low of 45.02% in Q4 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	450.31%
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	51.73%
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-107.40%
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	21.10%
9	Abivax	91.96 Bn	91.96 Bn	-	-50.43%
10	MapLight Therapeutics	248.88 Mn	248.88 Mn	-	-45.02%

Historic Data

Download Data

Date	Value
Dec 31, 2025	-45.02%